Risk and outcomes of diabetes in patients with epilepsy

Chun-Cheng Li1,2, Chuen-Chau Chang2,3,4, Yih-Giun Cherng1,2, Chao-Shun Lin2,3,4, Chun-Chieh Yeh5,6, Yi-Cheng Chang7,8,9, Chaur-Jong Hu10, Chun-Chuan Shih11, Ta-Liang Chen2,4,12,15 & Chien-Chang Liao2,3,4,13,14,15

The risk and outcomes of diabetes in patients with epilepsy remains unclear. We evaluated these risks using an epilepsy cohort analysis and a diabetes admission analysis. In the epilepsy cohort analysis, we identified 2854 patients with newly diagnosed epilepsy in 2000–2008 from the research data of National Health Insurance in Taiwan. Using Propensity-score matching by sociodemographic factors and medical conditions, we selected 22,832 people without epilepsy as a non-exposed cohort for comparison. Follow-up events of diabetes from January 1, 2000 until December 31, 2013 were ascertained from medical claims. The adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of diabetes associated with epilepsy were calculated using multiple Cox proportional hazard models. In the diabetes admission analysis, we identified 92,438 hospitalized diabetes patients, 930 of whom had a history of epilepsy. Adjusted odds ratios (ORs) and 95% CIs of adverse events after diabetes associated with previous epilepsy were calculated using multiple logistic regressions. The adjusted HR of diabetes in the cohort with epilepsy was 1.31 (95% CI 1.14–1.50) compared to the non-epilepsy cohort. Previous epilepsy was associated with post-diabetes adverse events, such as pneumonia (OR 1.68, 95% CI 1.37–2.07), urinary tract infection (OR 1.83, 95% CI 1.55–2.16), and septicemia (OR 1.34, 95% CI 1.09–1.65). In conclusion, epilepsy was associated with higher risk of diabetes and adverse post-diabetes outcomes. Diabetes prevention and attention to post-diabetes adverse events are needed for this susceptible population.

Abbreviations
ICD-9-CM  International classification of diseases, 9th revision, clinical modification
CI  Confidence interval
OR  Odds ratio
HR  Hazard ratio

Epilepsy is a disorder of the brain characterized by an enduring predisposition to seizures1. In the United States, approximately 2.5 million people have epilepsy, and it contributes to $12.5 billion in direct and indirect costs each year2. Although the cause of epilepsy is not completely understood, some risk factors have been identified, such as genetic conditions, abnormalities in brain development, stroke, head injuries, infections, tumors, or brain damage during or after birth3.

Diabetes is the most common metabolic and endocrine disease, affecting 6.9% of people in the United States4. It has been estimated that at least 20% of American adults over the age of 18 will have diabetes by the year...
Previous studies have shown that patients with diabetes have a higher predisposition to develop epilepsy\(^{10,11}\). In contrast, the risk of diabetes in patients with epilepsy is not completely understood due to limitations of previous investigations, such as inappropriate study design, small sample size, and inadequate adjustment for confounding factors\(^ {12-16}\). In addition, the impact of epilepsy on the outcomes after diabetes has not been validated. Using the reimbursement claims of the Taiwan National Health Research Database, we conducted this study included two analyses to investigate the risk and outcomes of diabetes in patients with epilepsy.

**Methods**

**Source of data.** In this study, we used the research data of the representative sample included one million persons in the Taiwan's National Health Insurance. Details of this database were described in the previous studies\(^ {9,17-19}\). There is no direct human participation in this study. Our study was approved by the Joint Institutional Review Boards of Taipei Medical University (TMU-JIRB-201801059; TMU-JIRB-201701050; TMU-JIRB-201912046). The Joint Institutional Review Boards of Taipei Medical University waived the need for informed consent of this study. All methods were carried out in accordance with relevant guidelines and regulations.

**Study design.** There were two analyses in the present investigation. In Analysis I (the retrospective cohort analysis), we excluded data from individuals with previous medical histories of diabetes and/or epilepsy from 1996 to 1999 in the cohort included 1,000,000 persons. The cohort with incident epilepsy included 2854 adults aged ≥ 20 years who were identified in the 2000–2008. These patients had at least one visit of outpatient or inpatient care for epilepsy. We used propensity-score matching procedure by sociodemographic factors and medical conditions at the same study time interval to select 22,832 adults as the cohort without epilepsy and all of them had no medical history of epilepsy. Therefore, members of both the cohorts with and without epilepsy had no history of diabetes at the beginning of follow-up period. We started the follow-up period in 2000 and it continued until the end of 2013. Incident cases of diabetes were identified during the follow-up period. The aim of this analysis was to evaluate the risk of diabetes in patients with epilepsy.

In Analysis II, we identified 92,438 patients with admission of types 2 diabetes admission in 2004–2013, 930 of them had epilepsy previously. We compared the short-term outcomes between diabetes patients with and without epilepsy including complications, the consumption of medical resources, and the case fatality within 30 days during or after hospitalization.

**Definitions and measurements.** People with low income were identified according to the definition of the Ministry of Health and Welfare, Taiwan. Physicians’ diagnostic codes from the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) were used to define diseases and morbidities in this study, such as diabetes (250) and epilepsy (345). Coexisting medical conditions included mental disorders (290–319), hypertension (401–405), chronic obstructive pulmonary disease (491, 492, and 496), head injury (800–804 and 850–854), stroke (430–438), ischemic heart disease (410–414), asthma, hyperlipidemia (272.0, 272.1, and 272.2), liver cirrhosis (571.2, 571.5, and 571.6), heart failure (428), and atrial fibrillation (427.3). Post-diabetes complications included sepsis (038 and 998.5), pneumonia (480–486) and urinary tract infection (599.0). Renal dialysis included hemodialysis and peritoneal dialysis were also recorded by the administrative code (D8 and D9).

**Statistical analysis.** In Analysis I, we used a propensity-score matching procedure (exposure vs nonexposure ratio = 1:8) to select patients with and without epilepsy. A non-parsimonious multivariable logistic regression model was used to estimate a propensity score for patients with and without epilepsy. Clinical significance guided the initial choice of covariates in this model to include age, sex, low income, mental disorders, hypertension, chronic obstructive pulmonary disease, traumatic brain injury, stroke, ischemic heart disease, asthma, hyperlipidemia, liver cirrhosis and heart failure. We matched people with epilepsy to people without epilepsy using a greedy matching algorithm (without replacement) with a caliper width of 0.2 SD of the log odds of the estimated propensity score. The chi-square tests were used to examine the distributions of categorical data, including such as (age, sex, low income, and history of diseases) between people with and without epilepsy. Using the multiple Cox proportional hazards models, the hazard ratios (HRs) with 95% confidence intervals (CIs) for diabetes risk in the cohort with epilepsy were calculated with the adjustment of all covariates. The stratified analyses were used to evaluate the risk of diabetes in patients with epilepsy within subgroups.

In Analysis II, differences in the balances of age, sex, low income, history of diseases, and medications between diabetes patients with and without epilepsy were examined using chi-square tests. We performed multiple logistic regressions to estimate odds ratios (ORs) and 95% CIs of complications and mortality after diabetes in patients with epilepsy by adjusting for sociodemographic factors and history of diseases. All significance tests were two-sided using \( p < 0.05 \) as the level of significance. All data analyses were performed with SAS, version 9.1 (SAS Institute Inc., Cary, NC, USA) statistical software.
### Results

The distributions of age, sex, low income, mental disorders, hypertension, chronic obstructive pulmonary disease, traumatic brain injury, stroke, ischemic heart disease, asthma, hyperlipidemia, liver cirrhosis and heart failure were balanced between cohorts with and without epilepsy because propensity-score matching was used in the Analysis I (Table 1).

The cohort with epilepsy had a higher incidence of diabetes than the non-epilepsy cohort (10.3 vs. 8.19 per 1000 person-years, \( P < 0.0001 \)) and the corresponding HR of diabetes associated with epilepsy was 1.31 (95% CI 1.14–1.50) during the follow-up period (Table 2). In the subgroup analysis, the association between epilepsy and risk of diabetes was significant in women (HR 1.23, 95% CI 1.01–1.51), men (HR 1.38, 95% CI 1.15–1.65), and those aged 30–39 years (HR 1.66, 95% CI 1.09–2.52), 50–59 years (HR 1.45, 95% CI 1.10–1.91), and 70–79 years (HR 1.45, 95% CI 1.04–2.00).

Among the 92,438 patients with diabetes admission (Table 3), patients with epilepsy had higher proportions of males (\( P < 0.0001 \)), older people (\( P < 0.0001 \)), low income (\( P < 0.0001 \)), stay in medical center (\( P < 0.0001 \)), mental disorders (\( P < 0.0001 \)), stroke (\( P < 0.0001 \)), chronic obstructive pulmonary disease (\( P < 0.0001 \)), ischemic heart disease (\( P = 0.001 \)), traumatic brain injury (\( P < 0.0001 \)), liver cirrhosis (\( P < 0.0001 \)), asthma (\( P = 0.0476 \)), congestive heart failure (\( P = 0.0314 \)), and atrial fibrillation (\( P = 0.0156 \)) compared with non-epilepsy patients.

Table 4 shows that patients with epilepsy had a higher risk of urinary tract infection (OR 1.51, 95% CI 1.37–1.67), pneumonia (OR 1.68, 95% CI 1.37–2.07), and septicemia (OR 1.34, 95% CI 1.09–1.65) after diabetes admission compared with those without epilepsy in the Analysis I.

The supplemental file (Table S1) demonstrates that the risk of diabetes was more significant in patients with epilepsy who had alcohol-related illness (HR 1.64, 95% CI 1.12–2.40). The epilepsy-related clinical indicators also had impacts on post-diabetes adverse events, such as generalized seizure (OR 1.42, 95% CI 1.02–1.98), low income (OR 1.80, 95% CI 1.18–2.74), emergency care (OR 1.81, 95% CI 1.41–2.34), and traumatic brain injury (OR 1.59, 95% CI 1.09–2.33).

### Discussion

Using the data from the Taiwan’s National Health Insurance, our Analysis I showed patients with epilepsy had an increased risk of diabetes during the follow-up period. In the Analysis II, we found the increased risk of pneumonia, urinary tract infection, and septicemia in patients with diabetes who had a history of epilepsy. Our investigation is the first population-based study showing the associated risk and outcomes of diabetes for patients with epilepsy.

---

**Table 1.** Characteristics of study subjects with and without epilepsy. COPD chronic obstructive pulmonary disease. *After propensity-score matching procedure, both groups have no atrial fibrillation or renal dialysis.
### Table 2. Risk of diabetes in association with epilepsy stratified by age and sex. CI confidence interval, HR hazard ratio. *Adjusted for all covariates listed in Table 1. † Per 1000 person-years.

|                      | n   | Events | Person-years | Incidence† | HR (95% CI)* |
|----------------------|-----|--------|--------------|------------|--------------|
| No epilepsy          | 22,832 | 1715 | 209,303 | 8.19 | 1.00 (Reference) |
| Epilepsy             | 2854 | 269 | 26,223 | 10.3 | 1.31 (1.14–1.50) |
| **Female**           |     |      |            |            |              |
| No epilepsy          | 10,320 | 826 | 94,457 | 8.74 | 1.00 (Reference) |
| Epilepsy             | 1290 | 126 | 11,916 | 10.6 | 1.23 (1.01–1.51) |
| **Male**             |     |      |            |            |              |
| No epilepsy          | 12,512 | 889 | 114,847 | 7.74 | 1.00 (Reference) |
| Epilepsy             | 1364 | 143 | 14,307 | 10.0 | 1.38 (1.15–1.65) |
| **Age, 20–29 years** |     |      |            |            |              |
| No epilepsy          | 5928 | 137 | 55,775 | 2.46 | 1.00 (Reference) |
| Epilepsy             | 741 | 23 | 7150 | 3.22 | 1.07 (0.64–1.79) |
| **Age, 30–39 years** |     |      |            |            |              |
| No epilepsy          | 3968 | 146 | 37,130 | 3.93 | 1.00 (Reference) |
| Epilepsy             | 496 | 29 | 4700 | 6.17 | 1.66 (1.09–2.52) |
| **Age, 40–49 years** |     |      |            |            |              |
| No epilepsy          | 4360 | 409 | 39,760 | 10.3 | 1.00 (Reference) |
| Epilepsy             | 545 | 64 | 5023 | 12.7 | 1.26 (0.96–1.67) |
| **Age, 50–59 years** |     |      |            |            |              |
| No epilepsy          | 2864 | 399 | 25,460 | 15.7 | 1.00 (Reference) |
| Epilepsy             | 358 | 64 | 2876 | 22.3 | 1.45 (1.10–1.91) |
| **Age, 60–69 years** |     |      |            |            |              |
| No epilepsy          | 2152 | 319 | 18,966 | 16.8 | 1.00 (Reference) |
| Epilepsy             | 269 | 40 | 2471 | 16.2 | 1.00 (0.71–1.42) |
| **Age, 70–79 years** |     |      |            |            |              |
| No epilepsy          | 2528 | 259 | 22,651 | 11.4 | 1.00 (Reference) |
| Epilepsy             | 316 | 42 | 2848 | 14.7 | 1.45 (1.04–2.00) |
| **Age, ≥ 80 years**  |     |      |            |            |              |
| No epilepsy          | 1032 | 46 | 9561 | 4.81 | 1.00 (Reference) |
| Epilepsy             | 129 | 7 | 1156 | 6.06 | 1.39 (0.63–3.09) |

### Table 3. Characteristics of hospitalized diabetes patients with and without previous epilepsy. COPD chronic obstructive pulmonary disease. *New-diagnosed diabetes after epilepsy.

|                      | Epilepsy* |     |          |     |          |     |          | P       |
|----------------------|-----------|-----|----------|-----|----------|-----|----------|---------|
|                      | No (N = 91,508) | Yes (N = 930) |          |     |          |     |          |         |
|                      | n (%)      | n (%) |          |     |          |     |          |         |
| **Age, years**       |           |       |          |     |          |     |          |         |
| 20–29                | 1011 (1.1) | 17 (1.8) | <0.0001  |     |          |     |          |         |
| 30–39                | 3108 (3.4) | 64 (6.9) |          |     |          |     |          |         |
| 40–49                | 8745 (9.6) | 131 (14.1) |          |     |          |     |          |         |
| 50–59                | 18,712 (20.5) | 181 (19.5) |          |     |          |     |          |         |
| 60–69                | 22,201 (24.3) | 173 (18.6) |          |     |          |     |          |         |
| 70–79                | 25,109 (27.4) | 225 (24.2) |          |     |          |     |          |         |
| ≥ 80                 | 12,622 (13.8) | 139 (15.0) |          |     |          |     |          |         |
| **Sex**              |           |       |          |     |          |     |          | <0.0001 |
| Female               | 43,532 (47.6) | 349 (37.5) |          |     |          |     |          |         |
| Male                 | 47,976 (52.4) | 581 (62.5) |          |     |          |     |          |         |
| **Low income**       |           |       |          |     |          |     |          | <0.0001 |
|                      | 4990 (5.4) | 107 (11.5) |          |     |          |     |          |         |
| **Stay in Medical center** |       |       |          |     |          |     |          | <0.0001 |
|                      | 29,963 (32.7) | 221 (23.8) |          |     |          |     |          |         |
| **Coexisting medical conditions** |           |       |          |     |          |     |          | <0.0001 |
| Hypertension         | 34,462 (37.7) | 322 (34.6) | 0.0572 |     |          |     |          |         |
| Mental disorders     | 18,326 (20.0) | 307 (33.0) | <0.0001 |     |          |     |          |         |
| Stroke               | 8090 (9.9) | 195 (21.0) | <0.0001 |     |          |     |          |         |
| COPD                 | 11,907 (13.0) | 186 (20.0) | <0.0001 |     |          |     |          |         |
| Ischemic heart injury| 17,381 (19.0) | 137 (14.7) | 0.0010 |     |          |     |          |         |
| Traumatic brain injury| 4541 (5.0) | 130 (14.0) | <0.0001 |     |          |     |          |         |
| Renal dialysis       | 10,452 (11.4) | 104 (11.2) | 0.8195 |     |          |     |          |         |
| Liver cirrhosis      | 4319 (4.7) | 75 (8.1) | <0.0001 |     |          |     |          |         |
| Asthma               | 5207 (5.7) | 67 (7.2) | 0.0476 |     |          |     |          |         |
| Heart failure        | 7262 (7.9) | 56 (6.0) | 0.0314 |     |          |     |          |         |
| Hyperlipidemia       | 5187 (5.7) | 44 (4.7) | 0.2184 |     |          |     |          |         |
| Atrial fibrillation  | 796 (0.9) | 15 (1.6) | 0.0156 |     |          |     |          |         |
renal dialysis, and stroke also commonly coexist with diabetes. The abovementioned diseases have also been identified as common comorbidities of epilepsy in previous studies. These factors were potential confounders when analyzing the association between epilepsy and risk of diabetes. To avoid confounding bias when investigating this relationship, we adjusted these sociodemographic factors and coexisting medical conditions in the multivariate regression models.

There are some possible reasons that may explain why patients with epilepsy had increased risk and adverse outcomes of diabetes. First, it has been reported that patients with epilepsy have increased cortisol levels. The activation of the hypothalamus–pituitary–adrenal axis causes elevated cortisol. Hypercortisolism is responsible for the occurrence of dyslipidemia, insulin intolerance, and diabetes. Subclinical hypercortisolism may also contribute to the risk of diabetes. Second, people with epilepsy exercise less and tend to be more obese. Social stigma and concerns for injury discourage patients with epilepsy from exercise and activity. Concomitant somatic and psychological diseases also limit their participation in physical activity. Anti-epilepsy drugs can also stimulate appetite and cause lethargy, thereby contributing to weight gain, which is a common risk factor for diabetes. Third, epilepsy is highly associated with psychiatric disease. Depression and antipsychotic medications are known risk factors for diabetes. Fourth, patients with epilepsy are more likely to have low socioeconomic status, which may limit their knowledge, attitude, and practice for caring for impaired glucose homeostasis.

Our results showed epilepsy increases the risk of diabetes, which aligns with the findings of previous studies. However, little is known about the effect of gender on the association between epilepsy and diabetes. In a further analysis of this study, we found that the impact of epilepsy on risk of diabetes is significant in both male and female populations. Moreover, alcohol-related illness, severe mental disorder, low income, and emergency care for epilepsy further increase the risk of diabetes. This finding is reasonable because individuals with those factors usually have poor epilepsy control.

Our analysis also showed that patients with epilepsy have a higher risk of diabetes, except those who are older than 60 years of age. This phenomenon may be because the incidence of diabetes in the non-epilepsy group is lower among young people, therefore making the effect of epilepsy more prominent. Another possible explanation is that epilepsy severity decreases with age, making the impact of epilepsy on other diseases less evident in the elderly group.

In the Analysis II investigating in-hospital adverse outcomes, we found that the numbers of post-diabetes infections in patients with epilepsy are significantly higher than those without epilepsy. Although these findings have not been reported previously, one study of adverse postoperative outcomes in patients with epilepsy showed similar results. Epilepsy and related comorbidities are also responsible for increased risk of community-acquired pneumonia. Epilepsy itself is known to increase the risk of aspiration pneumonia due to increased oral secretions, impaired swallowing mechanism, and difficulty in attaining adequate patient positioning. Use of anti-epilepsy drugs also increases the risk of infection. Although the mechanism is unclear, anti-epilepsy drugs decrease the production of some proinflammatory cytokines, which might facilitate and worsen infection. We considered that the possibility that the difference of adverse events after diabetes admission between the epilepsy group and the non-epilepsy group could simply reflect the difference of events between the epilepsy group and the non-epilepsy group not related to diabetes. This is because adverse events, such as pneumonia and urinary tract infection, are not specific events to diabetes.

We also found that patients with epilepsy who had low income, alcohol-related disease, severe mental disorder, emergency care for epilepsy, and traumatic brain injury were at an increased risk of diabetes. This is reasonable because those patients typically have poor self-care and epilepsy control.

To the best of our knowledge, the present study is the first investigations reporting that epilepsy increases the risk of diabetes and poor post-diabetes outcomes. Previously, it was known that patients with epilepsy face a mortality rate 1.4–9.7 times greater than that of the general population. Causes of mortality include the underlying neurologic cause of epilepsy (stroke and cancer), sudden unexpected death in epilepsy, status epilepticus, consequence of seizure attack (accident, drowning, and aspiration pneumonia), suicide, and iatrogenic death. The impact of diabetes on patients with epilepsy could be more pronounced than that of other diseases because poor glycemic control and hyperglycemia are themselves associated with the severity of seizures in human and

|                          | No epilepsy, % | Epilepsy, % | OR       | (95% CI)    |
|--------------------------|----------------|-------------|----------|-------------|
| 30-day in-hospital mortality | 1.1            | 1.8         | 1.59     | (0.98–2.60) |
| Urinary tract infection  | 14.2           | 22.2        | 1.83     | (1.55–2.16) |
| Pneumonia                | 6.6            | 11.7        | 1.68     | (1.37–2.07) |
| Septicemia               | 8.5            | 11.4        | 1.34     | (1.09–1.65) |
| Medical expenditure, USD | 30.35 ± 4589   | 32.27 ± 4923 | P = 0.2150 |
| Length of hospital stay, days | 17.4 ± 26.6 | 18.0 ± 23.9 | P = 0.4743 |

Table 4. Adverse outcomes after diabetes admission in patients with epilepsy. CI confidence interval, OR odds ratio, USD United States dollars. ‘New-diagnosed diabetes after epilepsy.’ Adjusted for all covariates listed in Table 3.

Age, gender, and low income are known factors associated with diabetes. Several medical conditions, such as hypertension, mental disorders, ischemic heart disease, chronic obstructive pulmonary disease, asthma, renal dialysis, and stroke also commonly coexist with diabetes. The abovementioned diseases have also been identified as common comorbidities of epilepsy in previous studies. These factors were potential confounders when analyzing the association between epilepsy and risk of diabetes. To avoid confounding bias when investigating this relationship, we adjusted these sociodemographic factors and coexisting medical conditions in the multivariate regression models.

There are some possible reasons that may explain why patients with epilepsy had increased risk and adverse outcomes of diabetes. First, it has been reported that patients with epilepsy have increased cortisol levels. The activation of the hypothalamus–pituitary–adrenal axis causes elevated cortisol. Hypercortisolism is responsible for the occurrence of dyslipidemia, insulin intolerance, and diabetes. Subclinical hypercortisolism may also contribute to the risk of diabetes. Second, people with epilepsy exercise less and tend to be more obese. Social stigma and concerns for injury discourage patients with epilepsy from exercise and activity. Concomitant somatic and psychological diseases also limit their participation in physical activity. Anti-epilepsy drugs can also stimulate appetite and cause lethargy, thereby contributing to weight gain, which is a common risk factor for diabetes. Third, epilepsy is highly associated with psychiatric disease. Depression and antipsychotic medications are known risk factors for diabetes. Fourth, patients with epilepsy are more likely to have low socioeconomic status, which may limit their knowledge, attitude, and practice for caring for impaired glucose homeostasis.

Our results showed epilepsy increases the risk of diabetes, which aligns with the findings of previous studies. However, little is known about the effect of gender on the association between epilepsy and diabetes. In a further analysis of this study, we found that the impact of epilepsy on risk of diabetes is significant in both male and female populations. Moreover, alcohol-related illness, severe mental disorder, low income, and emergency care for epilepsy further increase the risk of diabetes. This finding is reasonable because individuals with those factors usually have poor epilepsy control.

Our analysis also showed that patients with epilepsy have a higher risk of diabetes, except those who are older than 60 years of age. This phenomenon may be because the incidence of diabetes in the non-epilepsy group is lower among young people, therefore making the effect of epilepsy more prominent. Another possible explanation is that epilepsy severity decreases with age, making the impact of epilepsy on other diseases less evident in the elderly group.

In the Analysis II investigating in-hospital adverse outcomes, we found that the numbers of post-diabetes infections in patients with epilepsy are significantly higher than those without epilepsy. Although these findings have not been reported previously, one study of adverse postoperative outcomes in patients with epilepsy showed similar results. Epilepsy and related comorbidities are also responsible for increased risk of community-acquired pneumonia. Epilepsy itself is known to increase the risk of aspiration pneumonia due to increased oral secretions, impaired swallowing mechanism, and difficulty in attaining adequate patient positioning. Use of anti-epilepsy drugs also increases the risk of infection. Although the mechanism is unclear, anti-epilepsy drugs decrease the production of some proinflammatory cytokines, which might facilitate and worsen infection. We considered that the possibility that the difference of adverse events after diabetes admission between the epilepsy group and the non-epilepsy group could simply reflect the difference of events between the epilepsy group and the non-epilepsy group not related to diabetes. This is because adverse events, such as pneumonia and urinary tract infection, are not specific events to diabetes.

We also found that patients with epilepsy who had low income, alcohol-related disease, severe mental disorder, emergency care for epilepsy, and traumatic brain injury were at an increased risk of diabetes. This is reasonable because those patients typically have poor self-care and epilepsy control.

To the best of our knowledge, the present study is the first investigations reporting that epilepsy increases the risk of diabetes and poor post-diabetes outcomes. Previously, it was known that patients with epilepsy face a mortality rate 1.4–9.7 times greater than that of the general population. Causes of mortality include the underlying neurologic cause of epilepsy (stroke and cancer), sudden unexpected death in epilepsy, status epilepticus, consequence of seizure attack (accident, drowning, and aspiration pneumonia), suicide, and iatrogenic death. The impact of diabetes on patients with epilepsy could be more pronounced than that of other diseases because poor glycemic control and hyperglycemia are themselves associated with the severity of seizures in human and
animal studies. This finding implies that epilepsy and diabetes have reciprocal effects and that poor control of both diseases can result in a vicious cycle.

This study has some limitations. First, the National Health Research Database lacks information on laboratory data, clinical examinations, socioeconomic factors, and lifestyle and thus those factors were not considered as covariates in this study. Second, the duration and severity of epilepsy are not available from the database. Thus, we could not analyze the severity-related effects of epilepsy on diabetes. Third, people with minor or well-controlled epilepsy may not consult a doctor. However, if epilepsy is associated with diabetes, this misclassification would lead to underestimation of the association between epilepsy and diabetes risk. In addition, although we adjusted for several major potential confounders, residual confounding effects are always possible. Finally, the use of retrospective data in this study could not confirm the causal inference for the association between epilepsy and diabetes risk. This study is based on the database in Taiwan, which means the generalizability to other races or countries is uncertain.

In conclusion, we investigated patients with epilepsy had an increased risk of diabetes and adverse post-diabetes outcomes. This study provided a comprehensive assessment of diabetes risk and short-term outcomes in patients with epilepsy. Since epilepsy is associated with diabetes and uncontrolled diabetes aggravates epilepsy, diabetes prevention is important in patients with epilepsy. Strategies for prevention such as education, healthier lifestyles, better access to medical service, and control of comorbidities are needed.

Received: 12 May 2021; Accepted: 6 September 2021
Published online: 23 September 2021

References
1. Fisher, R. S. et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46(4), 470–472 (2005).
2. Begley, C. E. et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 41(3), 342–351 (2000).
3. Sander, J. W. & Shorvon, S. D. Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry 61(5), 433–443 (1996).
4. Polonsky, K. S. The past 200 years in diabetes. N. Engl. J. Med. 367(14), 1332–1340 (2012).
5. Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E. & Williamson, D. F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr. 8, 29 (2010).
6. Paneni, F., Beckman, J. A., Creager, M. A. & Cosentino, F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 34(31), 2436–2443 (2013).
7. Beckman, J. A., Paneni, F., Cosentino, F. & Creager, M. A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 34(31), 2444–2452 (2013).
8. Herlitz, J. et al. Mortality and morbidity in diabetic and non-diabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 19(7), 698–703 (1996).
9. Yeh, C. C. et al. Adverse outcomes after noncardiac surgery in patients with diabetes: a nationwide population-based retrospective cohort study. Diabetes Care 36(10), 3216–3221 (2013).
10. Ramakrishnan, R. & Appleton, R. Study of prevalence of epilepsy in children with type 1 diabetes mellitus. Seizure 21(4), 292–294 (2012).
11. Schober, E., Otto, K. P., Dost, A., Jorch, N. & Holl, R. Association of epilepsy and type 1 diabetes mellitus in children and adolescents: is there an increased risk for diabetic ketoacidosis?. J. Pediatr. 160(4), 662–666 (2012).
12. Téllez-Zenteno, J. F., Matijevic, S. & Wiebe, S. Somatic comorbidity of epilepsy in the general population in Canada. Epilepsia 46(12), 1955–1962 (2005).
13. Baca, C. B., Vickrey, B. G., Caplan, R., Vassar, S. D. & Berg, A. T. Psychiatric and medical comorbidity and quality of life outcomes in childhood-onset epilepsy. Pediatrics 128(6), e1532–e1543 (2011).
14. Ottman, R. et al. Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey. Epilepsia 52(2), 308–315 (2011).
15. Gaitatzis, A., Sisodiya, S. M. & Sander, J. W. The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia 53(8), 1282–1293 (2012).
16. Selassie, A. W. et al. Epilepsy beyond seizure: a population-based study of comorbidities. Epilepsia Res. 108(2), 305–315 (2014).
17. Chang, C. C. et al. Postoperative adverse outcomes in surgical patients with epilepsy: a population-based study. Epilepsia 53(6), 987–994 (2012).
18. Lin, C. S. et al. Outcomes after surgery in patients with diabetes who used metformin: a retrospective cohort study based on a real-world database. BMJ Open Diabetes Res Care. 8(2), e001351 (2020).
19. Hsu, S. P. C. et al. Stroke risk and outcomes in epilepsy patients: two retrospective cohort studies based on National Health Insurance in Taiwan. Atherosclerosis 280, 147–154 (2019).
20. Cowie, C. C. et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. Population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 29(6), 1263–1268 (2006).
21. Galé, E. A. & Gillespie, K. M. Diabetes and gender. Diabetologia 44(1), 3–15 (2001).
22. Robbins, J. M., Vaccarino, V., Zhang, H. & Kasl, S. V. Socioeconomic status and type 2 diabetes in African American and non-Hispanic white women and men: evidence from the Third National Health and Nutrition Examination Survey. Am. J. Public Health 91(1), 76–83 (2001).
23. Aminoff, M. J., Simon, R. P. & Wiedemann, E. The hormonal responses to generalized tonic-clonic seizures. Brain 107( Pt 2), 569–578 (1984).
24. O’Toole, K. K., Hooper, A., Wakefield, S. & Maguire, J. Seizure-induced disinhibition of the HPA axis increases seizure susceptibility. Epilepsia 108(1), 29–43 (2014).
25. Schäcke, H., Döcke, W. D. & Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96(1), 23–43 (2002).
26. Chioldini, L. et al. Association of subclinical hypercortisolism with type 2 diabetes: a case-control study in hospitalized patients. Eur. J. Endocrinol. 153(6), 837–844 (2005).
27. Kobau, R. et al. Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: behavioral risk factor surveillance system, 2002. Epilepsy Behav. 9(3), 358–366 (2004).
28. Jallon, P. & Picard, F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf. 24(13), 969–978 (2001).
29. Mezuk, B., Eaton, W. W., Albrecht, S. & Golden, S. H. Depression and type 2 diabetes over the lifespan: a meta-analysis. *Diabetes Care* **31**(12), 2383–2390 (2008).
30. Sernyak, M. J., Douglas, D. L., Alarcon, R. D., Losonczy, M. F. & Rosenheck, R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. *Am. J. Psychiatry* **159**(4), 561–566 (2002).
31. Ferguson, P. L. et al. Prevalence of self-reported epilepsy, health care access, and health behaviors among adults in South Carolina. *Epilepsy Behav.* **13**(3), 529–534 (2008).
32. Roberts, J. L. et al. Health-related behaviors and comorbidities in people with epilepsy: changes in the past decade. *Epilepsia* **56**(12), 1973–1981 (2015).
33. Moran, N. F. et al. Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. *Seizure* **13**(4), 561–566 (2002).
34. Torres, A., Peeterness, W. E., Vieggi, G. & Blasi, F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax* **68**(11), 1057–1065 (2013).
35. DeToledo, J. C., Lowe, M. R., Gonzalez, J. & Haddad, H. Risk of aspiration pneumonia after an epileptic seizure: a retrospective analysis of 1634 adult patients. *Epilepsy Behav.* **5**(4), 593–595 (2004).
36. Himmerich, H. et al. Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro. *J. Psychiatr. Res.* **47**(11), 1751–1759 (2013).
37. Cockerell, O. C. et al. Mortality from epilepsy: results from a prospective population-based study. *Lancet* **344**(8927), 918–921 (1994).
38. Nevalainen, O. et al. Epilepsy-related clinical characteristics and mortality: a systematic review and meta-analysis. *Neurology* **83**(21), 1968–1977 (2014).
39. Huang, C. W. et al. Diabetic hyperglycemia is associated with the severity of epileptic seizures in adults. *Epilepsy Res.* **79**(1), 71–77 (2008).
40. Schauwecker, P. E. The effects of glycemic control on seizures and seizure-induced excitotoxic cell death. *BMC. Neurosci.* **13**, 94 (2012).

Acknowledgements
This study is based on data obtained from Taiwan's Ministry of Health and Welfare. The authors' interpretations and conclusions do not represent Taiwan's Ministry of Health and Welfare.

Author contributions
C.C.L. and C.C.L.: conception and design, analysis and interpretation of the data, drafting the article, critical revision of the manuscript for important intellectual content and final approval of the version to be published. C.C.C., Y.G.C., C.S.L., C.C.Y., Y.C.C., C.J.H., C.C.S., and T.L.C.: conception and design, interpretation of the data, critical revision of the manuscript for important intellectual content and final approval of the version to be published. All authors have read and approved the submitted manuscript. T.L.C. has equal contribution with the corresponding author.

Funding
Taiwan's Ministry of Science and Technology (MOST106-2314-B-038-036-MY3; MOST107-2221-E-038-009).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-98340-x.

Correspondence and requests for materials should be addressed to C.-C.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. This article and any third party material in this article are made available under a Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. 

© The Author(s) 2021